Clinical trials: Recurrent DIPG
Recurrent or Progressive Diffuse Intrinsic Pontine Glioma
Re-Irradiation of Progressive or Recurrent DIPG
This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)
- Trial name
- NCT03126266
- Testing
- re-irradiation
- Where
- 18 sites in Australia, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- University of Calgary
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine…
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
- Trial name
- NCT05096481
- Testing
- PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Nationwide Children's Hospital
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma
Phase I Study of Marizomib + Panobinostat for Children With DIPG
This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG).
- Conditions
- Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer
- Trial name
- DIPG (NCT04341311)
- Testing
- Marizomib, Panobinostat
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Glioma, Ependymoma
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the…
- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT03033992
- Testing
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Children's Oncology Group
Neoplasms
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
- Trial name
- KOURAGE (NCT03967093)
- Testing
- BXQ-350
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb